The company is developing the RAPID™ Biodynamic Haematogel wound treatment for use in the management of complex and slow healing complex wounds such as diabetic foot ulcers and pressure sores.
The UK Medicines and Healthcare Products Regulatory Agency (MHRA) have classified the RAPID™ Biodynamic Haematogel wound care treatment as a medicinal product and have approved the commencement of the RAPID-1 Diabetic Foot Ulcer Trial at The Royal London Hospital, Barts Health NHS Trust.